We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » IRA Has Drug Industry Nervous and Strategizing, Say Lawyers
IRA Has Drug Industry Nervous and Strategizing, Say Lawyers
Attorneys who work in the biopharmaceutical industry say the landmark $740 billion Inflation Reduction Act (IRA) — passed in August and beginning to go into effect this month to lower drug costs — is chaotic, hard to understand and has the drug industry very nervous.